Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRAT | O95237 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22529142 | 1.00 | LRAT (0.54) | LRATLMNAKDM4EALOX15MEN1 | |
| SCHEMBL10150168 | 1.00 | LRAT (0.54) | LRATLMNAKDM4EALOX15MEN1 | |
| SCHEMBL3671686 | 1.00 | LRAT (0.54) | LRATLMNAKDM4EALOX15MEN1 | |
| SCHEMBL11508038 | 1.00 | LRAT (0.54) | LRATLMNAKDM4EALOX15MEN1 | |
| SCHEMBL21001805 | 1.00 | LRAT (0.54) | LRATLMNAKDM4EALOX15MEN1 | |
| SCHEMBL12930881 | 1.00 | LRAT (0.54) | LRATLMNAKDM4EALOX15MEN1 | |
| SCHEMBL13374328 | 0.89 | LRAT (0.59) | LRATLMNAKDM4EALOX15MEN1 | |
| SCHEMBL13374330 | 0.89 | LRAT (0.59) | LRATLMNAKDM4EALOX15MEN1 | |
| SCHEMBL12930855 | 0.89 | LRAT (0.59) | LRATLMNAKDM4EALOX15MEN1 | |
| SCHEMBL12930856 | 0.89 | LRAT (0.59) | LRATLMNAKDM4EALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| EP-2037951-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | Sirion Therapeutics, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007150046-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | ALDH1A2, PDE6C, EYA2 | LRAT 55/4885LMNA 402/4885KDM4E 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.